|
Insulet Corporation (PODD) DCF Valuation
US | Healthcare | Medical - Devices | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Insulet Corporation (PODD) Bundle
Looking to assess the intrinsic value of Insulet Corporation? Our (PODD) DCF Calculator integrates real-world data with extensive customization capabilities, enabling you to refine your forecasts and enhance your investment strategies.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 738.2 | 904.4 | 1,098.8 | 1,305.3 | 1,697.1 | 2,090.9 | 2,576.1 | 3,173.9 | 3,910.3 | 4,817.7 |
| Revenue Growth, % | 0 | 22.51 | 21.49 | 18.79 | 30.02 | 23.2 | 23.2 | 23.2 | 23.2 | 23.2 |
| EBITDA | 77.0 | 110.3 | 139.6 | 109.5 | 323.6 | 262.6 | 323.5 | 398.6 | 491.0 | 605.0 |
| EBITDA, % | 10.43 | 12.2 | 12.7 | 8.39 | 19.07 | 12.56 | 12.56 | 12.56 | 12.56 | 12.56 |
| Depreciation | 27.9 | 55.4 | 57.4 | 63.2 | 72.8 | 101.5 | 125.0 | 154.0 | 189.7 | 233.8 |
| Depreciation, % | 3.78 | 6.13 | 5.22 | 4.84 | 4.29 | 4.85 | 4.85 | 4.85 | 4.85 | 4.85 |
| EBIT | 49.1 | 54.9 | 82.2 | 46.3 | 250.8 | 161.1 | 198.5 | 244.6 | 301.3 | 371.2 |
| EBIT, % | 6.65 | 6.07 | 7.48 | 3.55 | 14.78 | 7.71 | 7.71 | 7.71 | 7.71 | 7.71 |
| Total Cash | 376.1 | 947.6 | 791.6 | 674.7 | 704.2 | 1,322.2 | 1,629.0 | 2,007.0 | 2,472.7 | 3,046.5 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 82.8 | 83.8 | 161.0 | 205.6 | 359.7 | 301.4 | 371.4 | 457.5 | 563.7 | 694.5 |
| Account Receivables, % | 11.22 | 9.27 | 14.65 | 15.75 | 21.19 | 14.42 | 14.42 | 14.42 | 14.42 | 14.42 |
| Inventories | 101.0 | 154.3 | 303.2 | 346.8 | 402.6 | 454.3 | 559.7 | 689.5 | 849.5 | 1,046.7 |
| Inventories, % | 13.68 | 17.06 | 27.59 | 26.57 | 23.72 | 21.73 | 21.73 | 21.73 | 21.73 | 21.73 |
| Accounts Payable | 54.5 | 54.1 | 37.7 | 30.8 | 19.2 | 84.8 | 104.5 | 128.8 | 158.7 | 195.5 |
| Accounts Payable, % | 7.38 | 5.98 | 3.43 | 2.36 | 1.13 | 4.06 | 4.06 | 4.06 | 4.06 | 4.06 |
| Capital Expenditure | -170.9 | -166.5 | -122.7 | -157.3 | -75.6 | -289.5 | -356.7 | -439.5 | -541.5 | -667.1 |
| Capital Expenditure, % | -23.15 | -18.41 | -11.17 | -12.05 | -4.45 | -13.85 | -13.85 | -13.85 | -13.85 | -13.85 |
| Tax Rate, % | 3.87 | 3.87 | 3.87 | 3.87 | 3.87 | 3.87 | 3.87 | 3.87 | 3.87 | 3.87 |
| EBITAT | 39.3 | 38.5 | 67.4 | 21.7 | 241.1 | 120.9 | 148.9 | 183.5 | 226.1 | 278.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -233.0 | -127.3 | -240.4 | -167.5 | 16.8 | 5.1 | -238.5 | -293.8 | -362.0 | -445.9 |
| WACC, % | 9.75 | 9.72 | 9.76 | 9.65 | 9.8 | 9.74 | 9.74 | 9.74 | 9.74 | 9.74 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -945.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -455 | |||||||||
| Terminal Value | -5,877 | |||||||||
| Present Terminal Value | -3,693 | |||||||||
| Enterprise Value | -4,638 | |||||||||
| Net Debt | 712 | |||||||||
| Equity Value | -5,350 | |||||||||
| Diluted Shares Outstanding, MM | 74 | |||||||||
| Equity Value Per Share | -72.66 |
What You Will Get
- Real Insulet Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Insulet’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.
Key Features
- 🔍 Real-Life PODD Financials: Pre-filled historical and projected data for Insulet Corporation.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Insulet’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Insulet’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Download the Template: Get instant access to the Excel-based Insulet Corporation (PODD) DCF Calculator.
- Input Your Assumptions: Adjust yellow-highlighted cells for growth rates, WACC, margins, and more.
- Instant Calculations: The model automatically updates Insulet’s intrinsic value.
- Test Scenarios: Simulate different assumptions to evaluate potential valuation changes.
- Analyze and Decide: Use the results to guide your investment or financial analysis.
Why Choose Insulet Corporation (PODD)?
- Innovative Technology: Cutting-edge insulin delivery systems designed for convenience and efficiency.
- Enhanced Patient Experience: User-friendly devices that improve the quality of life for individuals with diabetes.
- Strong Market Presence: A leader in the diabetes management sector with a proven track record.
- Commitment to Research: Ongoing investment in development to provide the latest advancements in diabetes care.
- Endorsed by Healthcare Professionals: Trusted by clinicians for its reliability and effectiveness in patient management.
Who Should Use Insulet Corporation (PODD)?
- Healthcare Professionals: Understand the latest advancements in insulin delivery systems and their impact on patient care.
- Researchers: Utilize cutting-edge data for studies on diabetes management and technology integration.
- Investors: Evaluate investment opportunities by analyzing the performance and market potential of Insulet Corporation (PODD).
- Analysts: Enhance your analysis with a comprehensive overview of Insulet's financial health and growth prospects.
- Diabetes Educators: Stay informed about innovative products and their benefits for patients managing diabetes.
What the Template Contains
- Pre-Filled DCF Model: Insulet Corporation’s (PODD) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Insulet Corporation’s (PODD) profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.